Related Experiment Video
Updated: Mar 20, 2026
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
Renal and Hematologic Toxicity Profile of [177] Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT): A
Merve Yalçınkaya1, Fadime Demir2, Seyhan Karaçavuş2
1Department of Internal Medicine, EğirdirStateHospital, Isparta, Turkey.
Objective:
This study aims to retrospectively evaluate the renal and hematologic toxicity profile of 177Lu-PSMA-RLT in patients with metastatic castration-resistant prostate cancer.
Methods:
Renal function (GFR, BUN, and creatinine) and hematological parameters (hemoglobin, leukocyte, platelet) before and after treatment were examined in 41 patients who received 177Lu-PSMA-RLT at our clinic, and changes along with toxicity grades were determined. Additionally, pre-treatment PSMA PET/CT findings and other demographic and clinical data were assessed.
Results:
In terms of renal toxicity, G0-G1 level toxicity was observed in 97.6% of cases, while G2 toxicity was observed in only one patient. This patient already had a low GFR before treatment and experienced only a 2-unit decrease. Regarding hematological toxicity, the rates of G3-4 toxicity were as follows: leukocytes 7.3%, hemoglobin 9.8%, platelets 7.3%.
Conclusion:
No clinically significant nephrotoxicity was observed with 177Lu-PSMA-RLT. Hematologic toxicity is significant but manageable, and severe side effects are rare and within predictable limits.
